Literature DB >> 10524430

Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope.

I F Ciernik1, P Romero, J A Berzofsky, D P Carbone.   

Abstract

BACKGROUND: p53 point mutations represent potential tumor-specific cytolytic T lymphocyte (CTL) epitopes. Whether ionizing radiation (IR) alters the immunological properties of cells expressing mutant p53 in respect of the CTL epitope generated by a defined point mutation has not been evaluated.
METHODS: Mutant p53-expressing syngeneic, nontumor forming BALB/c 3T3 fibroblasts, tumor forming ras-transfected BALB/c 3T3 sarcomas, and DBA/2-derived P815 mastocytoma cells, which differ at the level of minor histocompatibility antigens, were used as cellular vaccines. Cells were either injected with or without prior IR into naive BALB/c mice. Cellular cytotoxicity was assessed after secondary restimulation of effector spleen cells in vitro.
RESULTS: Injection of P815 mastocytoma cells expressing the mutant p53 induced mutation-specific CTL in BALB/c mice irrespective of prior irradiation. However, syngeneic fibroblasts or fibrosarcomas endogenously expressing mutant p53 were able to induce significant mutation-specific CTL only when irradiated prior to injection into BALB/c mice. IR of fibroblasts did not detectably alter the expression of cell surface molecules involved in immune response induction, nor did it alter the short-term in vitro viability of the fibroblasts. Interestingly, radioactively-labeled fibroblasts injected into mice after irradiation showed altered organ distribution, suggesting that the in vivo fate of these cells may play a crucial role in their immunogenicity.
CONCLUSIONS: These findings indicate that IR can alter the immunogenicity of syngeneic normal as well as tumor forming fibroblasts in vivo, and support the view that ionizing radiation enhances immunogenicity of cellular tumor vaccines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10524430     DOI: 10.1016/s0360-3016(99)00226-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery.

Authors:  Juan Carlos López Alfonso; Jan Poleszczuk; Rachel Walker; Sungjune Kim; Shari Pilon-Thomas; Jose J Conejo-Garcia; Hatem Soliman; Brian Czerniecki; Louis B Harrison; Heiko Enderling
Journal:  JCO Clin Cancer Inform       Date:  2019-04

2.  Radiation-induced tumor neoantigens: imaging and therapeutic implications.

Authors:  Christopher D Corso; Arif N Ali; Roberto Diaz
Journal:  Am J Cancer Res       Date:  2011-01-25       Impact factor: 6.166

3.  IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.

Authors:  Yimin Shi; Lillia Dincheva-Vogel; Charles E Ayemoba; Jeffrey P Fung; Cristina Bergamaschi; George N Pavlakis; Farzin Farzaneh; Karin M L Gaensler
Journal:  Blood Adv       Date:  2018-11-27

4.  A tumor-immune interaction model for hepatocellular carcinoma based on measured lymphocyte counts in patients undergoing radiotherapy.

Authors:  Wonmo Sung; Clemens Grassberger; Aimee Louise McNamara; Lucas Basler; Stefanie Ehrbar; Stephanie Tanadini-Lang; Theodore S Hong; Harald Paganetti
Journal:  Radiother Oncol       Date:  2020-07-15       Impact factor: 6.280

5.  A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer.

Authors:  Christoph Reissfelder; Carmen Timke; Hubertus Schmitz-Winnenthal; Nuh N Rahbari; Moritz Koch; Felix Klug; Falk Roeder; Lutz Edler; Jürgen Debus; Markus W Büchler; Philipp Beckhove; Peter E Huber; Jürgen Weitz
Journal:  BMC Cancer       Date:  2011-09-30       Impact factor: 4.430

6.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.

Authors:  Eric A Reits; James W Hodge; Carla A Herberts; Tom A Groothuis; Mala Chakraborty; Elizabeth K Wansley; Kevin Camphausen; Rosalie M Luiten; Arnold H de Ru; Joost Neijssen; Alexander Griekspoor; Elly Mesman; Frank A Verreck; Hergen Spits; Jeffrey Schlom; Peter van Veelen; Jacques J Neefjes
Journal:  J Exp Med       Date:  2006-04-24       Impact factor: 14.307

7.  Radiation, inflammation, and immune responses in cancer.

Authors:  Gabriele Multhoff; Jürgen Radons
Journal:  Front Oncol       Date:  2012-06-04       Impact factor: 6.244

8.  Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.

Authors:  Bin Zhang; Natalie A Bowerman; Joseph K Salama; Hank Schmidt; Michael T Spiotto; Andrea Schietinger; Ping Yu; Yang-Xin Fu; Ralph R Weichselbaum; Donald A Rowley; David M Kranz; Hans Schreiber
Journal:  J Exp Med       Date:  2007-01-08       Impact factor: 14.307

9.  High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up.

Authors:  Hiromichi Ishiyama; Takefumi Satoh; Masashi Kitano; Ken-ichi Tabata; Shouko Komori; Masaomi Ikeda; Itaru Soda; Shinji Kurosaka; Akane Sekiguchi; Masaki Kimura; Shogo Kawakami; Masatsugu Iwamura; Kazushige Hayakawa
Journal:  J Radiat Res       Date:  2013-11-11       Impact factor: 2.724

10.  Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports.

Authors:  Sarah A Milgrom; Yago Nieto; Chelsea C Pinnix; Grace L Smith; Christine F Wogan; Gabriela Rondon; L Jeffrey Medeiros; Partow Kebriaei; Bouthaina S Dabaja
Journal:  J Med Case Rep       Date:  2016-07-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.